<DOC>
	<DOCNO>NCT00393978</DOCNO>
	<brief_summary>The objective study determine whether treatment may useful reduce cannabis consumption ; reduce symptom bipolar mania ; weight mitigation therapy individual psychopharmacotherapy .</brief_summary>
	<brief_title>Efficacy Study Quetiapine Plus Topiramate Reducing Cannabis Consumption Bipolar Mania</brief_title>
	<detailed_description>The purpose research study study effect ( good bad ) combine medicine , call quetiapine topiramate , treat symptom , child adolescent ' symptom , bipolar mania ( illness period elation , excessive excitement , irritability , high energy , race thought , poor sleep , poor judgment , reckless behavior ) . It estimate 1 % population adolescent United States bipolar disorder . The purpose research study also study effect ( good bad ) combine two medicine , quetiapine topiramate , reduce use , child adolescent ' use , cannabis ( commonly refer `` pot '' ) . It estimate 30.5 % adolescent United States use cannabis least lifetime . Additionally , purpose research look bipolar disorder cannabis use effect brain chemical function . Quetiapine ( market brand name Seroquel ) approve FDA since 1997 help adult suffer schizophrenia ( illness feeling , think , perception behavior ) . On January 12 , 2004 , FDA approve quetiapine treatment bipolar symptom adult . As December 2009 , Quetiapine approve FDA use adolescent ( 13-17 year age ) treatment schizophrenia treatment manic episode associate bipolar I disorder child adolescent ( 10-17 year age ) . Bipolar disorder illness characterize recurrent mood swing include mania ( i.e. , period elation , excessive excitement , irritability , high energy , race thought , poor sleep , poor judgment , reckless behavior ) clinical depression ( i.e. , depress mood , loss interest activity disruption sleep , appetite energy ) . This study carry see quetiapine effective safe treatment child adolescent symptom bipolar mania . This study also carry see quetiapine , combination topiramate , reduce bipolar mania reduce cannabis use . As December 2 , 2009 , US Food Drug Administration ( FDA ) approve SEROQUEL ( quetiapine fumarate ) tablets treatment schizophrenia adolescent ( 13-17 year age ) monotherapy , acute treatment manic episode associate bipolar I disorder child adolescent ( 10-17 year age ) , monotherapy adjunct lithium divalproex . Topiramate ( market brand name Topamax ) approve U.S. FDA prevention migraine headache adult . The FDA also approve topiramate epilepsy ( seizure disorder ) use adjunctive therapy ( mean combination medicine ) partial onset seizure adult . Topiramate approve FDA use adult use child adolescent bipolar disorder . This study do see topiramate , combination quetiapine , reduce bipolar mania reduce cannabis use . The FDA declare research study MRI field strengths include 8 Tesla ( measure field strength ) non-significant risk . This research study use MRI field strength 4 Tesla .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Inclusion/Exclusion Criteria To include , subject must… authorized parent/legal guardian understand nature study provide write informed consent study subject young 18 year age . Additionally , subject must provide assent study ; fluent English ; 12 21 year age , inclusive ; use medically accept mean contraception ( i.e. , oral contraceptive barrier method ( diaphragm condom ) , medroxyprogesterone acetate injectable suspension , abstinence ) female menarche . Oral contraceptive alone acceptable mean contraception concomitant use topiramate low estrogen oral contraceptive pill may lead oral contraceptive failure ; diagnosis bipolar I disorder current manic mixed episode , addition cannabis use disorder ( include abuse dependence ) within 28 day prior screen , determine WASHUKSADS ; initial YMRS total score &gt; 16 screen baseline ; use cannabis minimum twice per week average 28 day prior screen . Subjects eligible participation they… know history mental retardation ; acutely intoxicate , thus impair ; manic depressive symptom result entirely acute medical illness acute intoxication withdrawal drug alcohol , determine medical evaluation rapid symptom resolution ; clinically significant alcohol drug withdrawal symptom , determine vital sign , The Clinical Institute Withdrawal Assessment Alcohol Scale Revised ( CIWAAr ) 24 , physician interview ; unstable medical neurological illness determine study physician ; laboratory abnormality &gt; 3 time upper limit establish normal value ; female , positive serum ( screen week 16 ) urine pregnancy test ( baseline week 116 ) , lactate , practice reliable form birth control ; history nephrolithiasis , since topiramate associate elevate risk kidney stone ; require concurrent treatment mood stabilizer , anticonvulsant , antidepressant require concurrent treatment carbonic anhydrase inhibitor . significant suicidal ideation treat substance use disorder 28 day prior screen courtordered treatment substance use ensure , detect change use topiramate treatment , likely due confound factor might influence substance use . Peer support group consider treatment substance use . **Patients enrol study already enrol court order substance treatment , least 1 month prior study enrollment , still meet minimum cannabis use criterion . ** diagnose treated eating disorder , make sure weight loss contribute already underlying condition family history glaucoma , since topiramate associate elevate risk glaucoma ; history nonresponse hypersensitivity quetiapine topiramate ; scanning , claustrophobia and/or contraindicate magnetic resonance scanning ( i.e . intraocular metallic object , brace , cochlear implant , pacemaker , electrical , mechanical , magnetically activated implant ) ; scan , history significant head trauma ( i.e . injury result loss consciousness great five minute ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Bipolar mania</keyword>
	<keyword>Cannabis consumption</keyword>
</DOC>